Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, and High Risk Myelodysplastic Syndrome

Trial Profile

A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, and High Risk Myelodysplastic Syndrome

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB 102 Mustang Bio (Primary) ; Cyclophosphamide; Decitabine; Fludarabine
  • Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mustang Bio
  • Most Recent Events

    • 05 Aug 2019 According to a Mustang Bio media release, the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate this trial.
    • 24 Jul 2019 According to a Mustang Bio media release, the company expect to initiate this trial in the coming months.
    • 18 Mar 2019 According to a Mustang Bio media release, the company expects to initiate a multicenter Phase 1/2 trial of MB-102 in acute myeloid leukemia BPDCN and high-risk myelodysplastic syndrome in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top